Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab
| Autor: | Byung Il Kim, Kyeong Min Kim, Sung Hyun Yang, Seung Sook Lee, Sang Moo Lim, Ilhan Lim, Chang Woon Choi, Tae Hyun Choi, Jae Pil Hwang, Joon Yeun Park, Hye Jin Kang |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
131I-rituximab
medicine.medical_specialty business.industry medicine.medical_treatment Hematology General Medicine medicine.disease Lymphoma Non-Hodgkin's lymphoma medicine.anatomical_structure Refractory immune system diseases hemic and lymphatic diseases Radioimmunotherapy medicine Fdg pet ct In patient Radiology business B cell |
| Zdroj: | Acta Haematologica. 130:74-82 |
| ISSN: | 1421-9662 0001-5792 |
| DOI: | 10.1159/000346436 |
| Popis: | Aims: It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas, treated by radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti-CD20 monoclonal antibody rituximab (131I-rituximab). Methods: Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of 131I-rituximab. Contrast-enhanced 18F-FDG PET/CT scans were performed before and after 1 month of RIT. Tumor sizes and maximum standardized uptake values (SUVmax) of scans were measured. Results: Four of the 24 patients survived. High SUVmax in a pretreatment scan was found to be related to poorer overall survival (OS) and progression-free survival (p = 0.04 and 0.02, respectively). Furthermore, a large tumor size in a pretreatment scan was associated with poorer OS but not with progression-free survival (p < 0.01 and p = 0.07, respectively). By multivariate analyses, a high SUVmax, a large tumor size in a pretreatment scan and diffuse large B-cell lymphoma histology were significantly associated with poorer OS [p = 0.04/hazard ratio (HR) = 3.54, p < 0.01/HR = 5.52, and p = 0.02/HR = 3.38, respectively). Conclusion: SUVmax and tumor size determined by a pretreatment 18F-FDG PET/CT result as significant predictors of OS in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated by RIT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|